Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-3.27 Insider Own0.60% Shs Outstand170.78M Perf Week0.56%
Market Cap16.63B Forward P/E- EPS next Y-1.06 Insider Trans-30.13% Shs Float170.17M Perf Month2.39%
Income-531.00M PEG- EPS next Q-0.38 Inst Own99.20% Short Float3.83% Perf Quarter26.48%
Sales973.70M P/S17.08 EPS this Y-17.30% Inst Trans-1.63% Short Ratio3.56 Perf Half Y23.29%
Book/sh11.79 P/B8.26 EPS next Y73.20% ROA-15.10% Target Price119.06 Perf Year-17.33%
Cash/sh2.95 P/C33.05 EPS next 5Y25.00% ROE-23.90% 52W Range62.12 - 120.61 Perf YTD-7.03%
Dividend- P/FCF- EPS past 5Y-21.30% ROI-4.20% 52W High-19.24% Beta1.32
Dividend %- Quick Ratio2.10 Sales past 5Y18.80% Gross Margin82.10% 52W Low56.79% ATR3.34
Employees2158 Current Ratio3.00 Sales Q/Q20.00% Oper. Margin-65.20% RSI (14)53.27 Volatility4.02% 3.29%
OptionableYes Debt/Eq0.35 EPS Q/Q-409.70% Profit Margin-54.50% Rel Volume0.44 Prev Close97.45
ShortableYes LT Debt/Eq0.34 EarningsOct 27 AMC Payout- Avg Volume1.83M Price97.40
Recom1.70 SMA201.53% SMA502.10% SMA20010.80% Volume812,500 Change-0.05%
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-20-16Initiated Credit Suisse Outperform
Jan-19-16Reiterated Wedbush Neutral $125 → $117
Nov-25-15Reiterated Oppenheimer Perform $119 → $115
Nov-18-15Initiated Goldman Buy
Oct-05-15Reiterated Wedbush Neutral $131 → $137
Oct-02-15Initiated Raymond James Outperform $148
Sep-01-15Initiated Raymond James Outperform $148
Jul-08-15Reiterated RBC Capital Mkts Outperform $145 → $155
Jun-19-15Downgrade Robert W. Baird Outperform → Neutral $125 → $133
Jun-18-15Reiterated Sun Trust Rbsn Humphrey Buy $151 → $170
Jun-18-15Reiterated RBC Capital Mkts Outperform $125 → $145
Jun-18-15Reiterated Piper Jaffray Overweight $123 → $147
Jun-18-15Reiterated Jefferies Buy $135 → $150
Sep-22-16 10:52AM  Blue Jay Capital Betting On Big Returns From These Healthcare Stocks at Insider Monkey
Sep-21-16 02:56PM  Sarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling
01:34PM  Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action at Barrons.com
11:50AM  Patent Trial And Appeal Board Hands Sarepta Another Big Win
10:05AM  Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment
08:54AM  BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics GlobeNewswire
Sep-20-16 03:12PM  [$$] Sarepta Soars 100% in a Week Yet Remains a Buy at Barrons.com
02:17PM  Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy? at Motley Fool
11:32AM  Why Sarepta Approval is Good News for BioMarin, Alexion at Barrons.com
10:13AM  Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
06:55AM  Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
Sep-19-16 11:15PM  Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $13.1 million of Shares
Sep-15-16 11:49AM  Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News? at Barrons.com
11:19AM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : September 15, 2016
08:38AM  BioMarin Announces EMA Validation of Brineura (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease GlobeNewswire
Sep-14-16 03:27PM  SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen
01:59PM  [$$] Sarepta Rally Has Legs as FDA Critic Leaves Agency at Barrons.com
08:50AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : September 14, 2016
06:17AM  These 5 Biotech Stocks Are Ready for a Volatility Break
Sep-13-16 04:48PM  Low Valuation Ratios Lead to Strong Portfolio Returns
Sep-08-16 04:30AM  BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting GlobeNewswire
Sep-07-16 11:26AM  BioMarin Pharmaceutical Inc. (BMRN)s Setback Isnt Really A Setback at Insider Monkey
10:58AM  BioMarin's (BMRN) Brineura Review Period Extended by FDA
09:30AM  Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Sep-06-16 05:30PM  After-hours buzz: CMG, PLAY, AMD & more at CNBC
04:05PM  BioMarin Announces Update to Brineura (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease GlobeNewswire
Sep-01-16 01:53PM  Biotech Stocks: Look At Those Takeover Premiums! at Barrons.com
Aug-31-16 10:24AM  Biotech: In Unfamiliar Territory? at Barrons.com
08:30AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
08:20AM  3 Biotech Stocks Could Be the Next Big Takeover Targets at 24/7 Wall St.
Aug-26-16 11:06AM  What Do Analysts Think about BioMarins Return Potential?
10:40AM  Investors Can't Count on This Bonus From Pharma Deals
10:05AM  What Should We Expect from BioMarins Kuvan in 2016?
08:04AM  How Much Did BioMarins Lead Drug Vimizim Earn in 1H16?
Aug-25-16 01:04PM  Whats BioMarins Expected Revenue Growth in 2016 and 2017?
12:04PM  Why Roche Might Be Interested in BioMarin
10:00AM  BioMarins Valuation on a Price-to-Sales Basis: Does It Matter?
09:38AM  Biotech Stocks: Oops, She Did It Again at Barrons.com
Aug-24-16 11:17AM  [$$] Smaller Biotech Buyout Targets After Medivation at Barrons.com
09:54AM  Forbes Ranks BioMarin 10th Most Innovative Company in the World GlobeNewswire
Aug-23-16 09:44AM  4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss at Barrons.com
Aug-22-16 11:05PM  The $150 million winner and the losers in Pfizer's $14 billion takeout of Medivation at bizjournals.com +6.72%
05:57PM  Why Syngenta, Valeant Pharmaceuticals, and BioMarin Pharmaceutical Jumped Today at Motley Fool
05:25PM  Biotech's next big deal?
02:43PM  Betting on BioMarin at Bloomberg
01:14PM  Biotechs Rise on Bet Medivation Losers Will Look to Next Deal
11:57AM  Biotech stocks rally as investors bet on the next big tie-up at CNBC
11:16AM  BioMarin (BMRN) Stock Surges on Takeover Speculation
Aug-19-16 10:05AM  Break Up Gilead Sciences? Not So Fast at Barrons.com
Aug-18-16 11:10AM  What Are the Opportunities for Horizon in 2016?
Aug-16-16 10:20AM  Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock
Aug-12-16 09:30AM  The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
08:53AM  How to Play a Nasdaq Breakout
Aug-11-16 05:30PM  Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
05:02PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
01:04PM  BIOMARIN PHARMACEUTICAL INC Financials
Aug-10-16 04:00PM  Solid BioMarin Pharmaceutical Inc. Earnings, More to Come at Motley Fool
Aug-09-16 07:01PM  Cramer: Companies Are Issuing a Lot of Paper
01:21PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : August 9, 2016
09:00AM  BioMarin Announces Pricing of Public Offering of Common Stock GlobeNewswire
Aug-08-16 04:52PM  BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering
04:33PM  BioMarin Announces Public Offering of Common Stock GlobeNewswire
11:26AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016
09:33AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
09:31AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits
Aug-05-16 11:34AM  BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped
11:07AM  An Update on Shires Upcoming Milestones
Aug-04-16 09:49PM  Edited Transcript of BMRN earnings conference call or presentation 4-Aug-16 8:30pm GMT
04:47PM  BioMarin reports 2Q loss
04:18PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:03PM  BioMarin Announces Second Quarter 2016 Financial Results GlobeNewswire
10:40AM  Merrill Lynch Says the Time to Put Money Into Biotech Is Now at 24/7 Wall St.
07:07AM  Q2 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
Aug-03-16 09:36AM  5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
09:05AM  BioMarins Key Order-Driven Drugs: Vimizim and Naglazyme
09:04AM  Update on Analyst Recommendations for Alexion
08:57AM  Is a Surprise Coming for BioMarin Pharmaceutical (BMRN) This Earnings Season?
Aug-02-16 06:30PM  Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?
04:34PM  'We Can Get as High as $475: Biogen Soars on Takeover Speculation; What About Celgene, BioMarin? at Barrons.com
11:06AM  How Much Will BioMarins Kuvan Fetch in 2Q16?
11:05AM  Analyst Recommendations for Vertex Pharmaceuticals after 2Q16 Earnings
09:08AM  Is BioMarin Set to Become Profitable in 2017?
Aug-01-16 06:36PM  Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
12:04PM  BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
11:07AM  How Much Did Kalydeco Add to Vertexs Top Line?
09:11AM  BioMarin: How Much Revenue Growth in 2Q16?
Jul-31-16 11:14AM  BioMarin: Why So Many Buy Recommendations?
Jul-29-16 07:23PM  Sam Isaly Swaps 3 Health Care Stocks in Second Quarter
03:51PM  Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Jul-28-16 08:30AM  How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company at Forbes
08:15AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%
Jul-27-16 06:02PM  FDA Accepts BLA for BioMarins Cerliponase Alfa for CLN2 Disease, Form of Batten Disease GlobeNewswire +6.60%
05:41PM  5 Reasons bluebird bio Inc. Took Flight Today at Motley Fool
05:40PM  A breakthrough for biotech?
03:47PM  Biomarin Hemophilia Gene Therapy Advances on Strong Study Results
03:13PM  Biomarin developing gene therapy for hemophilia
02:30PM  BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress GlobeNewswire
08:20AM  JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now at 24/7 Wall St.
Jul-26-16 05:17PM  What Do Analysts Recommend for Shire?
01:06AM  New Voices in Medical Advocacy Often Are Patients at The Wall Street Journal
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; and Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Kyndrisa, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 044, BMN 045, and BMN 053 for DMD treatment; cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis; and BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate for the treatment of hemophilia A. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as alpha-N-acetyglucosaminidase. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Option Exercise29.3494,7912,780,915431,709Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Sale95.5694,7919,058,600378,584Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 15Option Exercise17.3342,577737,859421,161Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 15Sale94.8542,5774,038,360378,584Sep 19 06:41 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 26Option Exercise26.4915,000397,350128,878Aug 30 09:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 26Sale95.0615,0001,425,924113,878Aug 30 09:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 16Option Exercise17.5441,666730,822420,250Aug 17 04:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 16Sale91.4941,6663,811,868378,584Aug 17 04:37 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale99.334,000397,32042,944Aug 03 10:19 AM
Davis George EricEVP, General CounselAug 01Sale100.002,167216,70071,158Aug 03 10:13 AM
Mueller BrianVP, Corporate ControllerAug 01Sale100.0028728,70014,260Aug 03 10:12 AM
LAWLIS V BRYANDirectorJul 27Option Exercise17.331,10019,06314,960Jul 28 07:02 PM
LAWLIS V BRYANDirectorJul 27Sale95.391,100104,92713,860Jul 28 07:02 PM
LAWLIS V BRYANDirectorJul 22Option Exercise17.336,400110,91220,260Jul 26 06:57 PM
LAWLIS V BRYANDirectorJul 22Sale95.016,400608,06413,860Jul 26 06:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 18Option Exercise17.5441,666730,822420,250Jul 20 07:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 18Sale92.7241,6663,863,272378,584Jul 20 07:51 PM
Davis George EricEVP, General CounselJul 14Option Exercise38.592,656102,49573,325Jul 18 06:02 PM
Davis George EricEVP, General CounselJul 07Sale90.002,167195,03070,669Jul 11 04:45 PM
LAWLIS V BRYANDirectorJun 20Sale82.7755045,52413,860Jun 21 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Option Exercise17.5441,666730,822420,250Jun 20 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Sale80.5541,6663,356,196378,584Jun 20 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 06Sale89.141,649146,99246,944Jun 08 08:39 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Option Exercise39.0616,896659,95871,235Jun 02 06:21 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Sale89.8820,8411,873,12650,394Jun 02 06:21 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Option Exercise26.4915,000397,350130,914May 31 06:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Sale87.8115,0001,317,100115,914May 31 06:52 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 23Sale87.073,769328,18458,644May 25 02:57 PM
BAFFI ROBERTEVP, Technical OperationsMay 18Sale87.055,000435,249130,386May 19 03:53 PM
Davis George EricEVP, General CounselMay 10Sale86.324,658402,07975,540May 10 07:06 PM
Davis George EricEVP, General CounselMay 09Sale84.5510,000845,53280,198May 10 07:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise12.9960,000779,40020,000May 09 08:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale80.1550,0004,007,4450May 09 08:47 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 03Sale86.0341535,70163,072May 04 04:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 02Option Exercise12.9936,500474,135432,135May 04 10:11 AM
BIENAIME JEAN JACQUESChief Executive OfficerMay 02Sale85.0136,5003,102,931395,635May 04 10:11 AM
BIENAIME JEAN JACQUESChief Executive OfficerApr 06Option Exercise14.391,50021,585395,221Apr 07 08:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.391,50021,585393,721Apr 07 08:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfficerMar 04Sale88.421,255110,97046,882Mar 07 08:45 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale86.124,623398,12049,688Mar 02 08:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 01Sale84.2810,000842,769340,500Mar 02 08:38 PM
GREY MICHAEL GDirectorFeb 22Option Exercise38.597,500289,42533,750Feb 23 04:41 PM
GREY MICHAEL GDirectorFeb 22Sale80.007,500600,00026,250Feb 23 04:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 30Sale94.741,00094,74425,758Dec 02 06:58 PM
GREY MICHAEL GDirectorNov 16Option Exercise38.597,500289,42533,750Nov 18 04:49 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Option Exercise39.0620,000781,20048,229Nov 18 04:03 PM
LAWLIS V BRYANDirectorNov 16Option Exercise17.337,500129,97519,350Nov 18 05:10 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Sale104.3020,0002,085,91828,229Nov 18 04:03 PM
GREY MICHAEL GDirectorNov 16Sale104.277,500782,05426,250Nov 18 04:49 PM
LAWLIS V BRYANDirectorNov 16Sale104.261,050109,46811,850Nov 18 05:10 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 02Sale117.56263,05735,605Nov 06 05:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 15Sale108.241,000108,24126,758Oct 19 01:39 PM